Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01467160 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.
JAMA Ophthalmol
January 2025
John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, Department of Neurology, University of Utah Health, Salt Lake City.
Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.
Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide.
ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritis.
Clin Rheumatol
January 2025
Faculty of Medicine, Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.
Objectives: To determine the features of rheumatoid pulmonary nodules and the factors associated with nodule progression in patients with rheumatoid arthritis.
Methods: Between January 2010 and September 2018, RA patients with at least one chest computed tomography (CT) were included. Two experienced radiologists examined chest CTs.
Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need.
Drugs Aging
January 2025
Department of Dermatology, University of Texas Health Science Center, 7979 Wurzbach Rd, Grossman 3rd FL, San Antonio, TX, 78229, USA.
Chronic itch in older patients is a common problem, with a significant impact on quality of life. Chronic itch in the older population may be attributable to several causes, such as age-related changes, skin conditions, systemic conditions, medications, and psychological conditions. Given the complexity of itch in this population, comorbidities, and polypharmacy in most geriatric patients, treating chronic itch can be challenging for healthcare providers.
View Article and Find Full Text PDFAnti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFUnraveling the role of autophagy regulation in Crohn's disease: from genetic mechanisms to potential therapeutics.
Adv Biotechnol (Singap)
March 2024
Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
Autophagy serves as the primary intracellular degradation mechanism in which damaged organelles and self-cytoplasmic proteins are transported to the lysosome for degradation. Crohn's disease, an idiopathic chronic inflammatory disorder of the gastrointestinal tract, manifests in diverse regions of the digestive system. Recent research suggests that autophagy modulation may be a new avenue for treating Crohn's disease, and several promising small-molecule modulators of autophagy have been reported as therapeutic options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!